Sotatercept clinical trials
Sotatercept is named as an intervention in 9 current clinical trials in our UK, USA, France, Spain, Netherlands, Canada, Israel, Germany, Italy, Poland, Mexico, Australia, Japan, Belgium, Sweden, Czechia, South Korea, Taiwan, Denmark, Switzerland, Portugal, Brazil, China, Singapore, Turkey and India registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Merck Sharp & Dohme LLC (6). The most-studied condition is Pulmonary Arterial Hypertension.
Where Sotatercept is approved
All regulators →Of the three regulators tracked here, the first to approve Sotatercept was the US, on 26 Mar 2024. It is approved in 3 of the 3 regulators tracked here.
- 1 EU orphan designation, most recently for treatment of pulmonary arterial hypertension (9 Dec 2020, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Sotatercept patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Sotatercept, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- Winrevair for treatment of pulmonary arterial hypertension: until 27 Aug 2034. Union Register
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Sotatercept
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Sotatercept works
All drug targets →- Inhibin beta A chain inhibitor InhibitorTarget: INHBA inhibin subunit beta AChEMBL only
- Eisenmenger syndromePhase 2
- AnemiaPhase 2
- Anemia (phenotype)Phase 2
- Beta thalassemiaPhase 2
- Chronic kidney diseasePhase 2
- Chronic myelomonocytic leukemiaPhase 2
- Myelodysplastic syndromePhase 2
- MyelofibrosisPhase 2
- Non-small cell lung carcinomaPhase 2
- Plasma cell myelomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1743073, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12962, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Sotatercept
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Sotatercept. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Sotatercept for treating pulmonary arterial hypertension NICE TA1161 | Optimised | 3 Jun 2026 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Sotatercept
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: WinrevairEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Sotatercept
- ChEMBL
- CHEMBL1743073
- DrugBank
- DB12118
- CAS number
- 1001080-50-7
- FDA UNII
- 0QI90BTJ37
- Wikidata
- Q103815273
- Wikipedia
- Sotatercept
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Sotatercept
9 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Sotatercept across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Sotatercept on the HPRA medicines list.
- Winrevair 45 mg powder and solvent for solution for injectionMerck Sharp & Dohme BV, · EU/1/24/1850/001-002
- Winrevair 60 mg powder and solvent for solution for injectionMerck Sharp & Dohme BV, · EU/1/24/1850/003-004
Supply shortages
No entry for Sotatercept in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Sotatercept
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 6 |
| Amsterdam UMC, location VUmc | 1 |
| University of Alberta | 1 |
| Kazuya Hosokawa | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Sotatercept trials
How many clinical trials are testing Sotatercept?
9 current trials in our UK, USA, France, Spain, Netherlands, Canada, Israel, Germany, Italy, Poland, Mexico, Australia, Japan, Belgium, Sweden, Czechia, South Korea, Taiwan, Denmark, Switzerland, Portugal, Brazil, China, Singapore, Turkey and India registers name Sotatercept (also registered as MK-7962) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are Sotatercept trials recruiting patients?
Yes. 6 of the 9 trials are recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 2 with sites in Netherlands, 1 with sites in Canada, 1 with sites in Israel, 1 with sites in Germany, 1 with sites in Poland, 1 with sites in Australia, 2 with sites in Japan, 1 with sites in Turkey and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Sotatercept clinical trials?
Merck Sharp & Dohme LLC (6), Amsterdam UMC, location VUmc (1), University of Alberta (1) and Kazuya Hosokawa (1). The number in brackets is how many trials each organisation leads.
Is Sotatercept licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Sotatercept, for example Winrevair 45 mg powder and solvent for solution for injection (Merck Sharp & Dohme BV,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Sotatercept shortage?
Not in the lists we track: Sotatercept has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sotatercept works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sotatercept works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sotatercept (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.